Clinical Trial Update: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1-2 advanced gastroenteropancreatic neuroendocrine tumors. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Lutetathera (Lutetium-177 DOTATATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | Phase 3 | Status: RECRUITING